Bacil Pharma Intrinsic Value
BACPHAR Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹12.21 | ₹9.77 - ₹14.65 | -70.0% | EPS: ₹0.40, Sector P/E: 22x |
| Book Value Method | asset | ₹35.71 | ₹32.14 - ₹39.28 | -12.3% | Book Value/Share: ₹17.86, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹12.21 | ₹10.99 - ₹13.43 | -70.0% | Revenue/Share: ₹0.71, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹16.28 | ₹14.65 - ₹17.91 | -60.0% | EBITDA: ₹1.00Cr, EV/EBITDA: 10x |
| PEG Ratio Method | growth | ₹12.21 | ₹10.99 - ₹13.43 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹12.21 | ₹10.99 - ₹13.43 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹12.68 | ₹11.41 - ₹13.95 | -68.9% | EPS: ₹0.40, BVPS: ₹17.86 |
Want to compare with current market value? Check BACPHAR share price latest .
Valuation Comparison Chart
BACPHAR Intrinsic Value Analysis
What is the intrinsic value of BACPHAR?
Based on our comprehensive analysis using 7 different valuation methods, the estimated intrinsic value of Bacil Pharma (BACPHAR) is ₹12.21 (median value). With the current market price of ₹40.71, this represents a -70.0% variance from our estimated fair value.
The valuation range spans from ₹12.21 to ₹35.71, indicating ₹12.21 - ₹35.71.
Is BACPHAR undervalued or overvalued?
Based on our multi-method analysis, Bacil Pharma (BACPHAR) appears to be trading above calculated value by approximately 70.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Debt to Equity Ratio | 1.04 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 4.0% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Asset Turnover Ratio | 0.04x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
Related Pages for Bacil Pharma
Additional stock information and data for BACPHAR
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-4 Cr | ₹-4 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |